[go: up one dir, main page]

WO2018034457A1 - Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espèce lactobacillus - Google Patents

Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espèce lactobacillus Download PDF

Info

Publication number
WO2018034457A1
WO2018034457A1 PCT/KR2017/008652 KR2017008652W WO2018034457A1 WO 2018034457 A1 WO2018034457 A1 WO 2018034457A1 KR 2017008652 W KR2017008652 W KR 2017008652W WO 2018034457 A1 WO2018034457 A1 WO 2018034457A1
Authority
WO
WIPO (PCT)
Prior art keywords
vesicles
lactobacillus
composition
bacteria
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/008652
Other languages
English (en)
Korean (ko)
Inventor
김윤근
한평림
최주리
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MD Healthcare Inc
Original Assignee
MD Healthcare Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170085020A external-priority patent/KR20180019474A/ko
Application filed by MD Healthcare Inc filed Critical MD Healthcare Inc
Priority to EP17841640.0A priority Critical patent/EP3501527B1/fr
Priority to CN201780050397.7A priority patent/CN109789175B/zh
Priority to US16/325,884 priority patent/US11583559B2/en
Priority to JP2019508939A priority patent/JP6763083B2/ja
Publication of WO2018034457A1 publication Critical patent/WO2018034457A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Definitions

  • the present invention relates to a composition for preventing, ameliorating, or treating mental disorders comprising the bacterium-derived vesicles of the genus Lactobacillus as an active ingredient.
  • Depression is a condition in which negative emotions occur due to changes in the brain's ability to control emotions, and more than 300 million people around the world suffer from it.
  • the number of depressed patients and total medical expenses increased by 4% and 10.4% per year, respectively.
  • Increased from 435,000 in 2005 to 500,300 in 2009 an increase of about 18,000 patients per year.
  • the increase rate of the elderly over 70 is the highest.
  • Depression is associated with chemical imbalances of neurotransmitters such as dopamine, serotonin and norepinephrine.
  • Serotonin is a neurometabolic compound found in cerebrospinal fluid, which circulates in the brain and functions as a neurotransmitter. Serotonin is closely related to the expression of emotions, and the lack of this material leads to unstable emotions, increasing anxiety and worry, and impulsive tendencies. Therefore, there are many drugs currently used as antidepressants to prevent the re-absorption of serotonin to stay in the brain for a long time.
  • the etiology of depression includes biological, psychological, sociological, pharmacological, and pathological factors that affect neurotransmitter imbalances, especially mental trauma from childhood accidents, assaults, and abuse. It is known that the probability of development is very high. This is because stress causes protein damage in the human brain. The stressful environment, ie the boom of selfishness, rapid industrialization, intense competition and a lack of social safety nets for the underprivileged are known to cause environmental factors.
  • Antidepressants used in the treatment of depression include tricyclic antidepressants such as imipramine, and selective serotonin reuptake inhibitors (SSRI).
  • SSRIs such as Trazodone and Mirtazapine
  • Trazodone and Mirtazapine have raised safety concerns, especially in older people, which may increase the risk of stroke, fracture, and death. .
  • the bacterium Lactobacillus is a gram-positive bacillus that grows well in anaerobic as well as aerobic environments and is found in fermented foods such as kimchi. In case of kimchi, other lactic acid bacteria die even if it is sour kimchi, but the bacterium is a viable bacterium that survives and decomposes polysaccharides such as galactose and arabinose well. Bacteria secrete extracellular vesicles (EVs), commonly referred to as nanovesicles or nanovesicles, as bilayer protein lipids into the extracellular environment for the exchange of information between proteins, lipids, genes, and the like.
  • EVs extracellular vesicles
  • Gram-positive bacteria-derived vesicles such as Lactobacillus plantarum and Lactobacillus casei, are not only bacteria-derived proteins and nucleic acids but also peptidoglycan, a cell wall component of bacteria. It also contains lipoteichoic acid.
  • Lactobacillus plantarum secretes factors that suppress depression in the brain, but vesicles secreted by Lactobacillus plantarum, or Lactobacillus casei, are stress and anxiety disorders.
  • Post-traumatic Stress Disorder PTSD
  • panic disorder depression
  • depression depression
  • Autism spectrum disorders depression
  • ADHD attention deficit / hyperactivity disorder
  • the present inventors have studied intensively to find a correlation between bacterial vesicles derived from Lactobacillus and psychiatric disorders. It was observed that the same level of anti-stress and anti-depressant effect, the present invention was completed based on this.
  • an object of the present invention is to provide a composition for preventing, ameliorating, or treating mental disorders, including a vesicle derived from Lactobacillus bacteria as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of mental disorders, including as an active ingredient vesicles derived from the genus Lactobacillus (Lactobacillus).
  • the present invention provides a health functional food composition for improving mental disorders, including Lactobacillus bacteria-derived vesicles as an active ingredient.
  • the present invention provides an inhalant composition for preventing or treating mental disorders, comprising a vesicle derived from Lactobacillus sp. As an active ingredient.
  • the mental illness is stress, anxiety disorder.
  • Post-traumatic Stress Disorder PTSD
  • panic disorder depression
  • Autism spectrum disorders PTSD
  • ADHD attention deficit / hyperactivity disorder
  • the vesicles may have an average diameter of 10 to 1000 nm.
  • the vesicles may be isolated from the bacterial culture medium of Lactobacillus (Lactobacillus).
  • the vesicles may be secreted naturally or artificially in bacteria of the genus Lactobacillus.
  • the vesicles may be to use the vesicles separated from the food prepared by adding bacteria of Lactobacillus (Lactobacillus).
  • the vesicles may be derived from Lactobacillus plantarum ( Lactobacillus plantarum ) or Lactobacillus casei ( Lactobacillus casei ).
  • the vesicles may be derived from Lactobacillus genus bacteria other than Lactobacillus plantarum and Lactobacillus casei .
  • the present invention also provides a method of preventing or treating mental disorders, comprising administering the composition to a subject.
  • the present invention provides a preventive or therapeutic use of psychiatric diseases of the bacteria-derived vesicles of the genus Lactobacillus.
  • Lactobacillus plantarum and Lactobacillus casei-derived vesicles were administered to stress and depression animal models, the resistance to stress was effectively increased, and there was an effect of treating chronic long-term depressive behavior.
  • Lactobacillus according to the invention bacteria-derived vesicles are stress, anxiety disorders. Useful in the development of medicines or dietary supplements to prevent, ameliorate, or treat mental disorders such as post-traumatic stress disorder, panic disorder, depression, autism spectra disorder, attention deficit hyperactivity syndrome, and schizophrenia Can be.
  • FIG. 1 graphically illustrates an experimental protocol for evaluating the antistress effect of Lactobacillus plantarum-derived vesicles (EV) in a stressed mouse model [CON or CON + Veh: Saline-administered normal mice (control) , Saline administration control group), CON + EV: vesicle administration normal mouse group, RST + Veh: saline administration stress treatment group, RST + EV: vesicle administration stress treatment group].
  • CON or CON + Veh Saline-administered normal mice (control) , Saline administration control group
  • CON + EV vesicle administration normal mouse group
  • RST + Veh saline administration stress treatment group
  • RST + EV vesicle administration stress treatment group
  • Figure 2a is a method for evaluating the anti-stress effect of the Lactobacillus plantarum-derived vesicles, and shows a U-Box test experimental method for measuring the sociality for each mouse group.
  • Figure 2b shows the results of the U-Box test for each group of mice in order to evaluate the anti-stress effect of the Lactobacillus plantarum-derived vesicles.
  • FIG. 3A and 3B show a tail suspension test (TST) (FIG. 3A) and a forced swim for each group of mice to evaluate the antistress effect of Lactobacillus plantarum derived vesicles. test; FST) (FIG. 3B) shows the results of each.
  • FIG. 4 graphically illustrates an experimental protocol for evaluating the antidepressant effects of Lactobacillus plantarum-derived vesicles (EV) in a mouse model induced by depression as a result of chronic stress [CON + Veh: normal saline administration] Mouse group, CON + EV: vesicle-administered normal mouse group, RST + Veh: saline-administered chronic stress treatment group, RST + EV: vesicle-administrated chronic stress treatment group, RST + IMI: imipramine-treated chronic stress treatment group].
  • Figure 5 shows the results of the U-Box test for each group of mice as a primary behavioral test to evaluate the antidepressant effect of Lactobacillus plantarum-derived vesicles.
  • TST tail behavioral tests
  • Figure 7 shows the results of the U-Box test for each group of mice as a second behavioral test to evaluate the antidepressant effect of Lactobacillus plantarum-derived vesicles.
  • FIG. 8A and 8B show a tail behavior test (TST) (FIG. 8A) and a forced swimming test (FST) for each group of mice as a secondary behavioral test for evaluating antidepressant effects of Lactobacillus plantarum-derived vesicles.
  • Fig. 8B shows the result.
  • L. casei EV L. casei EV
  • CON + veh saline administration control
  • CON + Lac vesicle-administered normal mouse group
  • RST + veh saline-administrated stress treatment group
  • RST + Lac vesicle-administrated stress treatment group
  • 10A, 10B, and 10C are first-order behavioral tests for evaluating antistress effects of Lactobacillus casei-derived vesicles, and performing a U-Box test (Fig. 10A) for each mouse group to find a target.
  • the results of evaluating behavior (FIG. 10b) and sociality index (FIG. 10c) are shown.
  • 11A and 11B are first-order behavioral tests for evaluating anti-stress effects of Lactobacillus casei-derived vesicles, and the tail suspension test (TST) (FIG. 11A) and forced swimming test for each group of mice. (forced swim test; FST) (FIG. 11B) shows the results of performing each.
  • 12A and 12B are secondary behavioral tests for evaluating the antidepressive effect of Lactobacillus casei-derived vesicles, and a U-Box test is performed on each mouse group to find a target (FIG. 12A) and sociality. The result of evaluating the index (FIG. 12B) is shown.
  • FIG. 13 is a secondary behavioral test for evaluating the antidepressant effect of Lactobacillus casei-derived vesicles, and shows a result of a tail suspension test (TST) for each mouse group.
  • TST tail suspension test
  • the present inventors have studied intensively to find a correlation between Lactobacillus bacteria-derived vesicles and mental disorders. And it was observed that the antidepressant effect, the present invention was completed based on this.
  • each of three types of behavioral tests namely, the U-BOX test, tailing test and forced test
  • the anti-stress effect was confirmed in the mice administered with the nanovesicles compared to the stress-treated mice by the swimming test (see Example 1).
  • the vesicles were analyzed by performing the same three kinds of behavioral tests. It was confirmed that the effect was shown (see Example 2).
  • the present invention provides a pharmaceutical composition for the prevention or treatment of mental disorders, including the Lactobacillus bacteria-derived vesicles as an active ingredient.
  • the term "psychiatric disease” refers to a morbid mental state that affects a person's thinking, emotions, and behaviors, and refers to a state in which a disorder in mental function has been brought.
  • the mental illness is stress, anxiety disorder. Post-traumatic Stress Disorder (PTSD), panic disorder, depression, Autism spectrum disorders, attention deficit / hyperactivity disorder (ADHD), and Schizophrenia and the like.
  • stress is a nonspecific biological response that occurs in the body to various injuries and stimuli to the living body, first named by Canadian endocrinologist H. celier.
  • the stress response is a stimulating hormone, adrenaline or other hormone, that is secreted into the blood to protect our bodies, providing the strength and energy to fight the danger or avoid the situation.
  • Common symptoms of stress vary, but physical symptoms such as fatigue, headache, insomnia, stomach disease, abdominal pain, vomiting, mental symptoms such as decreased concentration or memory, indecisiveness, emptiness, anxiety, nervousness, depression, anger, Emotional symptoms, such as frustration, and behavioral symptoms such as restlessness, nervous habits, and smoking.
  • depression disorder refers to a disease that causes various cognitive and psychosomatic symptoms due to decreased motivation and depression as main symptoms, leading to a decrease in daily functioning. Depression is known to be caused by environmental factors such as biochemical factors, genetic factors, and strong stress due to neurotransmitter or hormone imbalance. It is known to be prevented by the help of stress control, friendships and social support during times of crisis.
  • prophylaxis means any action that inhibits mental retardation or delays onset by administration of a pharmaceutical composition according to the present invention.
  • treatment refers to any action in which symptoms caused by mental disorders are improved or advantageously changed by administration of the pharmaceutical composition according to the present invention.
  • the vesicles of the present invention may be isolated from a culture solution of Lactobacillus bacteria or food prepared by adding Lactobacillus bacteria, and may be naturally or artificially secreted from Lactobacillus bacteria, but is not limited thereto. .
  • the method for separating the vesicles from the culture solution or fermented food of the bacteria of the Lactobacillus genus of the present invention is not particularly limited as long as the vesicles.
  • centrifugation, ultra-fast centrifugation, filtration by filter, gel filtration chromatography, pre-flow electrophoresis, or capillary electrophoresis, and combinations thereof may be used to separate the vesicles and also remove impurities. It may further include a process for washing, concentration of the obtained vesicles and the like.
  • the vesicles separated by the method in the present invention may have an average diameter of 10 to 1000 nm, but is not limited thereto.
  • the pharmaceutical composition according to the present invention includes a bacterium derived from Lactobacillus as an active ingredient, and may include a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are conventionally used in the preparation, and include, but are not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like. If necessary, other conventional additives such as antioxidants and buffers may be further included.
  • diluents, dispersants, surfactants, binders, lubricants and the like may be additionally added to formulate injectable formulations, pills, capsules, granules, or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • Suitable pharmaceutically acceptable carriers and formulations can be preferably formulated according to the individual components using methods disclosed in Remington's literature.
  • the pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated as an injection, inhalant, external preparation for skin, oral ingestion, and the like.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, skin, nasal, airways) according to the desired method, and the dosage is determined by the condition and weight of the patient, disease Depending on the degree, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
  • the composition according to the invention is administered in a pharmaceutically effective amount.
  • the pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to the medical treatment, and the effective dose level refers to the type, severity, drug activity, and drug of the patient. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • the composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the composition according to the present invention may vary depending on the age, sex, and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight is administered daily or every other day or 1 It can be administered in 1 to 3 times a day.
  • the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the present invention provides a health functional food composition for improving mental disorders comprising a bacterium derived from Lactobacillus bacteria as an active ingredient.
  • improvement means any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms.
  • the active ingredient may be added to the food as it is, or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient can be suitably determined according to the purpose of use (improving).
  • the compositions of the invention are added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw materials.
  • the amount may be below the above range.
  • the health functional food composition of the present invention in addition to containing the active ingredient as an essential ingredient in the indicated ratios, is not particularly limited to other ingredients, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of the natural carbohydrate can be appropriately determined by the choice of those skilled in the art.
  • the nutraceutical composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
  • these components can be used independently or in combination.
  • the proportion of such additives may also be appropriately selected by those skilled in the art.
  • the present invention also provides a prophylactic or therapeutic inhalant composition for mental disorders comprising the bacterium-derived vesicles of the genus Lactobacillus as an active ingredient.
  • the active ingredient may be added to the inhalant as it is, or may be used together with other ingredients, and may be appropriately used according to conventional methods.
  • the amount of the active ingredient to be mixed may be suitably determined depending on the purpose of use (prophylactic or therapeutic).
  • the present invention provides a method for preventing or treating mental disorders comprising administering to a subject a composition comprising a Lactobacillus bacteria-derived vesicle as an active ingredient.
  • an individual means a subject in need of treatment of a disease, and more specifically, a mammal such as a primate, mouse, rat, dog, cat, horse, and cow, which is human or non-human. Means.
  • mice 7-week-old male C57BL / 6 mice purchased four groups, that is, a normal group of mice administered saline (0.9% Saline, 100 ⁇ l) for 14 days (CON or CON) + Veh), normal mice group (CON + EV) administered nanovesicles (2 ug / mouse / 100 ⁇ l), saline (0.9% Saline, Group (RST + Veh) administered 100 ⁇ l) and nanovesicles (EV, 2 ug / mouse / 100 ⁇ l) to mice subjected to body detention stress for 14 days for 2 hours daily (RST + EV)
  • U-BOX test, tail suspension test (TST), and forced swim test (FST) which measure sociability, were performed in order. The antistress effect was evaluated.
  • the U-BOX test was performed on four groups of mice that performed the above experiments.
  • the test is to put the target mouse in the wire mesh on one side of the U-shaped field, the wire mesh without the target mouse on the other side, the experimental method for checking how much time to contact the target mouse to be.
  • both groups stayed with similar probability during the field adaptation period (Habituation, non-target condition, 5 minutes), but showed different results for each group under the target condition conducted for 10 minutes, which is the actual behavior test. That is, in the control group (CON + Veh) and the control group (CON + EV), the time spent in the target space was increased compared to the time spent in the non-target space.
  • Example 1 it was evaluated whether the depressive behavior induced as a result of chronic stress when Lactobacillus plantarum-derived nano-vesicles can be recovered.
  • 7 weeks old male C57BL / 6 mice were purchased in a random group of five mice, that is, a group of normal mice (saline (0.9% Saline, 100 ⁇ l) for 14 days (CON + Veh) ), Normal mice group (CON + EV) to which nanovesicles (EV, 2, 4, 6 ug / mouse / 100 ⁇ l) were administered, and saline (0.9% Saline, 100 ⁇ l) were added to chronic stressed mice for 14 days.
  • the nanovesicles are administered daily from the end of the stress treatment, but from 1 day (p1) to 4 days (p4) until 2 ug / mouse / 100 ⁇ l and 5 days (p5) to 6 days (p6) 4 ug / mouse / 100 ⁇ l, 7 days (p7) to 14 days (p14) were gradually increased to 6 ug / mouse / 100 ⁇ l.
  • FIG. 6 As a result of performing the tail-seal test (FIG. 6A) and the forced swimming test (FIG. 6B), respectively, in the stressed group (RST + Veh), compared to the control group (CON + Veh). While this significantly increased, in the stress-treated nanovesicles (RST + EV) and the imipramine group (RST + IMI) it was confirmed that the dead time was reduced to the control level.
  • mice were conducted to determine whether the induction of depressive behavior caused by stress when Lactobacillus casei-derived nanovesicles were used in combination.
  • 8-week-old male C57BL / 6 mice purchased four groups, that is, the normal group of mice administered saline (0.9% Saline, 100 ⁇ l) for 14 days (CON + veh) ), Normal mice group (CON + Lac) receiving nanovesicles (11 ug / mouse / 100 ⁇ l), saline (0.9% Saline, 100 ⁇ l) in mice subjected to body detention stress (RST) for 14 days for 2 hours each day.
  • RST body detention stress
  • mice subjected to the above experiments were subjected to a U-BOX test (sociability test) two weeks after stress administration.
  • the test is to put the target mouse in the wire mesh on one side of the U-shaped field, the wire mesh without the target mouse on the other side, the experimental method for checking how much time to contact the target mouse to be.
  • the U-BOX test (sociability test) was performed 4 weeks after the stress administration to the four groups of mice subjected to the above experiment.
  • the time spent in the target space was longer than the time spent in the non-target space.
  • the social index was significantly decreased in the group (RST + veh), compared to the control group, but the nano-vesicles were administered together with the physical detention stress.
  • the social index returned to the control level.
  • the present invention relates to a composition for preventing, ameliorating, or treating mental disorders comprising the Lactobacillus bacteria-derived vesicles as an active ingredient, and according to the present invention, comprising the Lactobacillus bacteria-derived vesicles as an active ingredient, mental illness
  • a composition for the prevention, improvement, or treatment of it is expected that it can be usefully used in the development of medicines or functional foods for preventing, improving symptoms, or treating future mental diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition permettant de prévenir, d'atténuer ou de traiter un trouble mental, la composition contenant une vésicule dérivée de bactéries d'une espèce de Lactobacillus utilisée comme principe actif. Les présents inventeurs ont confirmé que, lorsqu'une vésicule dérivée de bactéries d'une espèce de Lactobacillus est administrée à un modèle animal souffrant de stress et de dépression, la résistance au stress augmente efficacement, et un effet de traitement du comportement de dépression chronique durable sur le long terme est observé, et ainsi la vésicule dérivée de bactéries d'une espèce de Lactobacillus, selon la présente invention, est censée pouvoir être utilisée avec efficacité dans le développement d'un médicament ou d'un aliment santé fonctionnel, etc., destiné à prévenir, à réduire les symptômes ou à traiter un trouble mental tel que le stress, le trouble de l'anxiété, le trouble de stress post-traumatique, le trouble panique, la dépression, le trouble du spectre autistique, le trouble d'hyperactivité avec déficit de l'attention et la schizophrénie.
PCT/KR2017/008652 2016-08-16 2017-08-09 Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espèce lactobacillus Ceased WO2018034457A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP17841640.0A EP3501527B1 (fr) 2016-08-16 2017-08-09 Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espècelactobacillus
CN201780050397.7A CN109789175B (zh) 2016-08-16 2017-08-09 预防或治疗精神障碍的含源自乳酸杆菌属细菌的囊泡的组合物
US16/325,884 US11583559B2 (en) 2016-08-16 2017-08-09 Composition for preventing or treating mental disorder, containing Lactobacillus sp. bacteria-derived vesicle
JP2019508939A JP6763083B2 (ja) 2016-08-16 2017-08-09 ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2016-0103680 2016-08-16
KR20160103680 2016-08-16
KR10-2017-0085020 2017-07-04
KR1020170085020A KR20180019474A (ko) 2016-08-16 2017-07-04 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
KR10-2017-0100459 2017-08-08
KR1020170100459A KR101963957B1 (ko) 2016-08-16 2017-08-08 락토바실러스 속 세균 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2018034457A1 true WO2018034457A1 (fr) 2018-02-22

Family

ID=61196874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008652 Ceased WO2018034457A1 (fr) 2016-08-16 2017-08-09 Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espèce lactobacillus

Country Status (1)

Country Link
WO (1) WO2018034457A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205645A1 (fr) 2019-03-29 2020-10-08 Tdbt Ip Inc. Remplacements de tissus et d'organes et leurs procédés de fabrication
CN119524029A (zh) * 2025-01-23 2025-02-28 北京大学第六医院 旧金山乳杆菌预防和/或治疗注意缺陷多动障碍的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104738A1 (en) * 2003-07-15 2007-05-10 Irene Tatischeff Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104738A1 (en) * 2003-07-15 2007-05-10 Irene Tatischeff Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROWN, L. ET AL.: "Extracellular Vesicles Produced by the Gram-positive Bacterium Bacillus Subtilis Are Disrupted by the Lipopeptide Surfactin", MOLECULAR MICROBIOLOGY, vol. 93, no. 1, 2014, pages 183 - 198, XP055466011, DOI: doi:10.1111/mmi.12650 *
SCHERTZER, J. W. ET AL.: "Bacterial Outer Membrane Vesicles in Trafficking, Communication and the Host-pathogen Interaction", JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY, vol. 23, 2013, pages 118 - 130, XP009185196, DOI: doi:10.1159/000346770 *
See also references of EP3501527A4 *
ZABOROWSKI, M. P. ET AL.: "Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study", BIOSCIENCE, vol. 65, no. 8, 2015, pages 783 - 797, XP055466019, DOI: doi:10.1093/biosci/biv084 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205645A1 (fr) 2019-03-29 2020-10-08 Tdbt Ip Inc. Remplacements de tissus et d'organes et leurs procédés de fabrication
CN119524029A (zh) * 2025-01-23 2025-02-28 北京大学第六医院 旧金山乳杆菌预防和/或治疗注意缺陷多动障碍的用途
CN119524029B (zh) * 2025-01-23 2025-08-22 北京大学第六医院 旧金山乳杆菌预防和/或治疗注意缺陷多动障碍的用途

Similar Documents

Publication Publication Date Title
KR101963957B1 (ko) 락토바실러스 속 세균 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
Zhu et al. Microbiota-gut-brain axis and the central nervous system
US7785581B2 (en) Composition and method for reducing feces toxins and treating digestive disorders
KR102622219B1 (ko) 신규 유산균 및 이의 용도
Borre et al. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential
Borycka-Kiciak et al. Butyric acid–a well-known molecule revisited
KR20150133646A (ko) Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
Guo et al. Gut microbiome in neuroendocrine and neuroimmune interactions: The case of genistein
WO2018034430A1 (fr) Composition pour prévenir ou traiter un trouble mental, contenant une vésicule dérivée de lactobacillus plantarum
WO2018030732A1 (fr) Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation
TW201907927A (zh) 包含細菌菌株之組合物
Li et al. Antidepression of Xingpijieyu formula targets gut microbiota derived from depressive disorder
WO2018034457A1 (fr) Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espèce lactobacillus
WO2015064988A1 (fr) Composition pharmaceutique pour traiter ou prévenir une septicémie, contenant du nicotinamide riboside comme principe actif
Liu et al. Effect of Artemisia annua on anticoccidial action, intestinal microbiota and metabolites of Hu lambs
WO2015178653A1 (fr) Composition utilisable en vue du traitement ou de la prévention d'une maladie métabolique et contenant, en tant qu'ingrédient actif, des vésicules extracellulaires provenant de bactéries de l'espèce akkermansia muciniphila
CN106668034A (zh) L‑岩藻糖在治疗消化道病变的药品和保健品中应用
CN114642684B (zh) 用于防治焦虑抑郁症的直肠真杆菌（Eubacterium rectale）
WO2012064158A2 (fr) Composition comprenant des herbes médicinales fermentées pour le traitement du syndrome du côlon irritable
CN114699424B (zh) 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
WO2023204358A1 (fr) Aliment et composition pharmaceutique contenant des probiotiques pour prévenir ou traiter la démence
CN104971124A (zh) 一种药物组合物的新用途
CN117229943A (zh) 一株假小链双歧杆菌及其应用
CN116570582A (zh) 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用
CN114364391B (zh) 改善或抑制胃肠道不适的组合物及方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17841640

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019508939

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017841640

Country of ref document: EP

Effective date: 20190318